Susquehanna Fundamental Investments LLC Invests $10 Million in Revolution Medicines, Inc. (NASDAQ:RVMD)

Susquehanna Fundamental Investments LLC purchased a new stake in Revolution Medicines, Inc. (NASDAQ:RVMD) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 228,513 shares of the company’s stock, valued at approximately $9,995,000. Susquehanna Fundamental Investments LLC owned approximately 0.14% of Revolution Medicines as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its position in shares of Revolution Medicines by 14.7% during the fourth quarter. Vanguard Group Inc. now owns 17,096,455 shares of the company’s stock valued at $747,799,000 after buying an additional 2,185,082 shares during the last quarter. FMR LLC boosted its holdings in Revolution Medicines by 14.7% during the 4th quarter. FMR LLC now owns 6,742,083 shares of the company’s stock worth $294,899,000 after acquiring an additional 866,190 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of Revolution Medicines by 10.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,865,962 shares of the company’s stock worth $256,578,000 after acquiring an additional 552,657 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Revolution Medicines by 12.7% in the fourth quarter. Geode Capital Management LLC now owns 4,086,199 shares of the company’s stock valued at $180,171,000 after purchasing an additional 459,174 shares during the last quarter. Finally, Lord Abbett & CO. LLC lifted its position in shares of Revolution Medicines by 8.0% during the fourth quarter. Lord Abbett & CO. LLC now owns 1,978,720 shares of the company’s stock valued at $86,549,000 after purchasing an additional 146,699 shares in the last quarter. Institutional investors and hedge funds own 94.34% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on RVMD shares. Stifel Nicolaus dropped their target price on shares of Revolution Medicines from $78.00 to $64.00 and set a “buy” rating on the stock in a research report on Tuesday, April 1st. UBS Group boosted their price objective on Revolution Medicines from $65.00 to $71.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. HC Wainwright lifted their target price on Revolution Medicines from $72.00 to $73.00 and gave the stock a “buy” rating in a research note on Monday, March 3rd. Wedbush restated an “outperform” rating and set a $67.00 price target on shares of Revolution Medicines in a research report on Thursday, February 27th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $59.00 target price on shares of Revolution Medicines in a research note on Tuesday, April 8th. Twelve investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Revolution Medicines currently has an average rating of “Buy” and an average price target of $66.67.

Insider Buying and Selling at Revolution Medicines

In related news, CFO Jack Anders sold 1,864 shares of the stock in a transaction on Monday, March 17th. The stock was sold at an average price of $39.04, for a total value of $72,770.56. Following the sale, the chief financial officer now owns 115,006 shares in the company, valued at approximately $4,489,834.24. This trade represents a 1.59 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Margaret A. Horn sold 3,058 shares of the business’s stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $39.04, for a total value of $119,384.32. Following the transaction, the chief operating officer now owns 153,533 shares of the company’s stock, valued at approximately $5,993,928.32. The trade was a 1.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 16,660 shares of company stock valued at $650,406 in the last three months. Company insiders own 8.00% of the company’s stock.

Revolution Medicines Price Performance

Revolution Medicines stock opened at $38.77 on Friday. The firm has a market capitalization of $7.21 billion, a P/E ratio of -10.80 and a beta of 1.37. Revolution Medicines, Inc. has a one year low of $29.17 and a one year high of $62.40. The business has a fifty day moving average price of $37.43 and a 200-day moving average price of $44.05.

Revolution Medicines (NASDAQ:RVMD) last posted its earnings results on Wednesday, February 26th. The company reported ($1.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.11). Sell-side analysts expect that Revolution Medicines, Inc. will post -3.49 earnings per share for the current fiscal year.

Revolution Medicines Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.